Evolving myelodysplastic syndrome in an HIV patient with history of anal cancer and chemotherapy

Mingyue Shi, Xiaobang Hu, Mingyi Chen

Research output: Contribution to journalArticlepeer-review


The incidence of therapy-related myelodysplastic syndromes (t-MDS) has been increasing with the widespread use of highly active antiretroviral therapy (HAART) therapy for HIV and chemotherapy for AIDS-related cancers. The classical dysplastic features in the granulocytes and megakaryocytes may not be easily appreciated. The most reliable distinguishing feature between the hematopoietic dysplasia of t-MDS and that of HIV infection rests on the identification of MDS-related cytogenetic aberrations. Here we report a patient with well-controlled HIV and history of chemotherapy for invasive anal squamous cell carcinoma who developed high-risk t-MDS with complex chromosome abnormalities. Our study emphasizes the importance of diagnosis of MDS in HIV-infected patients, even in the absence of dysplasia, if there are typical cytogenetics changes of MDS. Therefore, the early diagnosis and intervention of t-MDS in HIV-positive patients are critical in the treatment of this aggressiveness disease.

Original languageEnglish (US)
Pages (from-to)213-214
Number of pages2
JournalJournal of Hematopathology
Issue number4
StatePublished - Dec 1 2019


  • Acquired immune deficiency syndrome
  • Cancer
  • Chemotherapy
  • HIV
  • Therapy-related myelodysplastic syndromes (t-MDS)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Hematology


Dive into the research topics of 'Evolving myelodysplastic syndrome in an HIV patient with history of anal cancer and chemotherapy'. Together they form a unique fingerprint.

Cite this